Potential of an Injectable Polymer to Prevent Hyperacute Rejection of Ex Vivo Perfused Porcine Lungs

Wiebe, Karsten; Oezkur, Mehmet; Pöling, Jochen; Haverich, Axel

doi:10.1097/01.tp.0000234819.18069.53

Cited by 5 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVLP has since been used not only for the assessment but also for the reconditioning of marginal and DCD donor lungs [5][6][7]. To date, several studies have been conducted using EVLP as a drug delivery system [8][9][10][11][12].…”

mentioning

confidence: 99%

β2-Adrenoreceptor Agonist Inhalation During Ex Vivo Lung Perfusion Attenuates Lung Injury

Kondo

Chen

Ohsumi

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

β2-Adrenoreceptor Agonist Inhalation During Ex Vivo Lung Perfusion Attenuates Lung Injury

Kondo

Chen

Ohsumi

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…85 Moreover, in the EVLP porcine model, perfusion with human blood modified by the addition of polymer GAS914, a soluble trisaccharide-polylysine conjugate, showed great potential in binding xenoreactive human antibodies and preserving the function of a porcine lung xenograft, thereby preventing hyperacute rejection in lung xenotransplantation. 86 These studies highlight the potential of donor lung immunomodulation via EVLP before transplantation in decreasing posttransplant rejection.…”

Section: Potential Benefits Of Evlp According To Clinical and Preclin...mentioning

confidence: 98%

Diagnostic and Therapeutic Implications of Ex Vivo Lung Perfusion in Lung Transplantation: Potential Benefits and Inherent Limitations

Zhang

et al. 2022

Transplantation

View full text Add to dashboard Cite

Ex vivo lung perfusion (EVLP), a technique in which isolated lungs are continually ventilated and perfused at normothermic temperature, is emerging as a promising platform to optimize donor lung quality and increase the lung graft pool. Over the past few decades, the EVLP technique has become recognized as a significant achievement and gained much attention in the field of lung transplantation. EVLP has been demonstrated to be an effective platform for various targeted therapies to optimize donor lung function before transplantation. Additionally, some physical parameters during EVLP and biological markers in the EVLP perfusate can be used to evaluate graft function before transplantation and predict posttransplant outcomes. However, despite its advantages, the clinical practice of EVLP continuously encounters multiple challenges associated with both intrinsic and extrinsic limitations. It is of utmost importance to address the advantages and disadvantages of EVLP for its broader clinical usage. Here, the pros and cons of EVLP are comprehensively discussed, with a focus on its benefits and potential approaches for overcoming the remaining limitations. Directions for future research to fully explore the clinical potential of EVLP in lung transplantation are also discussed.

show abstract

“…The development of GalTKO pigs was a major advance in lung xenotransplantation. While immunoadsorption or depletion of recipient anti‐Gal and other antibodies prior to engraftment is partially beneficial , knocking out α‐1,3 galactosyltransferase blocks expression of the Gal epitope , providing a more effective and durable means of limiting hyperacute rejection (Table ). With ex vivo xenoperfusion, median survival time is increased from 10 min for WT lungs to 120 min for the GalTKO genotype , a finding that correlates with improved life‐supporting function in vivo .…”

Section: Proven and Emerging Protective Strategiesmentioning

confidence: 99%

Lung xenotransplantation: recent progress and current status

Harris

Quinn

Dahi

et al. 2014

Xenotransplantation

View full text Add to dashboard Cite

Xenotransplantation has undergone important progress in controlling initial hyperacute rejection in many pre-clinical models, with some cell, tissue, and organ xenografts advancing toward clinical trials. However, acute injury, driven primarily by innate immune and inflammatory responses, continues to limit results in lung xenograft models. The purpose of this article is to review the current status of lung xenotransplantation – including the seemingly unique challenges posed by this organ – and summarize proven and emerging means of overcoming acute lung xenograft injury.

show abstract

Potential of an Injectable Polymer to Prevent Hyperacute Rejection of Ex Vivo Perfused Porcine Lungs

Abstract: In this ex-vivo lung perfusion model, a trisaccharide polymer prevented immediate HAR, due to effective removal of alpha-Gal antibodies. In combination with additional strategies GAS914 may be a valuable tool in overcoming HAR and dysfunction of pulmonary xenografts.

Cited by 5 publications

References 39 publications

β2-Adrenoreceptor Agonist Inhalation During Ex Vivo Lung Perfusion Attenuates Lung Injury

β2-Adrenoreceptor Agonist Inhalation During Ex Vivo Lung Perfusion Attenuates Lung Injury

Diagnostic and Therapeutic Implications of Ex Vivo Lung Perfusion in Lung Transplantation: Potential Benefits and Inherent Limitations

Lung xenotransplantation: recent progress and current status

Contact Info

Product

Resources

About